Director Senior Director of Market Access Policy Development

BillionToOne, is a next-generation molecular diagnostics company dedicated to developing powerful and accurate diagnostic tests that are accessible to all. The company's innovative QCT molecular counting technology significantly enhances the resolution of disease detection using cell-free DNA by over 1,000-fold. This groundbreaking technology is integral to BillionToOne's product offerings. One of BillionToOne’s flagship products, Unity Complete™, is the only non-invasive prenatal screen capable of assessing fetal risk for both common recessive conditions and aneuploidies from a single maternal blood sample. Leveraging the same molecular counting technology, BillionToOne is expanding its reach into oncology with a pioneering liquid biopsy test, Northstar, that combines treatment selection with monitoring. Over 500K patients have received BillionToOne tests to date, and BillionToOne has grown from $0M to $125M ARR in the last ~4 years.

Ranked at the top 5% of Y Combinator compa Apply now and work remotely at BillionToOne